Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis

Conclusion PBMC-derived TG2 mRNA levels hold promise as biomarker for disease progression in patients with MS. Classification of Evidence This study provides Class II evidence that in patients with MS, PBMC-derived TG2 mRNA levels are associated with disease progression.

http://nn.neurology.org/cgi/content/short/8/4/e998?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - April 27, 2021 Category: Neurology Authors: Sestito, C., Leurs, C. E., Steenwijk, M. D., Breve, J. J. P., Twisk, J. W. R., Wilhelmus, M. M. M., Drukarch, B., Teunissen, C. E., van Dam, A.-M., Killestein, J. Tags: MRI, Autoimmune diseases, Class II, Multiple sclerosis Article Source Type: research